

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Parex® REVLANE+ IGNIFUGE TALOCHE FIN

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Plaster admixtures

#### 1.3 Details of the supplier of the safety data sheet

Company name of supplier : Sika Limited  
Watchmead Welwyn Garden City  
Hertfordshire. AL7 1BQ  
Telephone : +44 (0)1707 394444  
Telefax : +44 (0)1707 329129  
E-mail address of person responsible for the SDS : EHS@uk.sika.com

#### 1.4 Emergency telephone number

National Chemical Emergency Centre (NCEC)  
24 Hour Emergency Telephone Number +44 870 190 6777

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Skin sensitisation, Category 1 H317: May cause an allergic skin reaction.  
Long-term (chronic) aquatic hazard, Category 2 H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H317 May cause an allergic skin reaction.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P261 Avoid breathing mist or vapours.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

|                  |   |
|------------------|---|
| P273             | Avoid release to the environment.                                 |
| P280             | Wear protective gloves.   |
| <b>Response:</b> |   |
| P333 + P313      | If skin irritation or rash occurs: Get medical advice/ attention. |
| P362 + P364      | Take off contaminated clothing and wash it before reuse.          |
| P391             | Collect spillage.   |

### Hazardous components which must be listed on the label:

1,2-benzisothiazol-3(2H)-one (BIT)  
2-octyl-2H-isothiazole-3-one (OIT)  
2-methyl-2H-isothiazol-3-one (MIT)  
mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) (C(M)IT/MIT (3:1))

### Additional Labelling

EUH211 Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

| Chemical name  | CAS-No.<br>EC-No.<br>Registration number         | Classification | Concentration<br>(% w/w) |
|--|--|----------------|--------------------------|
| titanium dioxide; [in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 µm] | 13463-67-7<br>236-675-5<br>01-2119489379-17-XXXX | Carc. 2; H351  | ≥ 1 - < 2,5              |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021

Version 1.1

Print Date 31.08.2021

Revision Date: 31.08.2021

|   |   |  |                                  |
|---|---|--|----------------------------------|
| <p>2-octyl-2H-isothiazole-3-one (OIT)</p> | <p>26530-20-1<br/>247-761-7<br/>01-2120768921-45-XXXX</p> | <p>Acute Tox. 3; H301<br/>Acute Tox. 2; H330<br/>Acute Tox. 3; H311<br/>Skin Corr. 1; H314<br/>Eye Dam. 1; H318<br/>Skin Sens. 1A; H317<br/>Aquatic Acute 1;<br/>H400<br/>Aquatic Chronic 1;<br/>H410<br/>EUH071</p> <hr/> <p>M-Factor (Acute aquatic toxicity):<br/>100100<br/>M-Factor (Chronic aquatic toxicity):<br/>100100</p> <hr/> <p>specific concentration limit<br/>Skin Sens. 1A; H317<br/>&gt;= 0,0015 %<br/>Skin Sens. 1A; H317<br/>&gt;= 0,0015 %</p> <hr/> <p>Acute toxicity estimate</p> <p>Acute oral toxicity:<br/>125 mg/kg<br/>125 mg/kg<br/>Acute inhalation toxicity (dust/mist): 0,27 mg/l<br/>0,27 mg/l<br/>Acute dermal toxicity:<br/>311 mg/kg<br/>311 mg/kg</p> | <p>&gt;= 0,0025 - &lt; 0,025</p> |
|---|---|--|----------------------------------|

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021

Version 1.1

Print Date 31.08.2021

Revision Date: 31.08.2021

|   |  |  |                                   |
|---|--|--|-----------------------------------|
| <p>1,2-benzisothiazol-3(2H)-one (BIT)</p> | <p>2634-33-5<br/>220-120-9<br/>01-2120761540-60-XXXX</p> | <p>Acute Tox. 4; H302<br/>Acute Tox. 2; H330<br/>Skin Irrit. 2; H315<br/>Eye Dam. 1; H318<br/>Skin Sens. 1; H317<br/>Aquatic Acute 1; H400<br/>Aquatic Chronic 2; H411</p> <hr/> <p>specific concentration limit<br/>Skin Sens. 1; H317<br/>&gt;= 0,05 %<br/>Skin Sens. 1; H317<br/>&gt;= 0,05 %</p>   | <p>&gt;= 0,0025 - &lt; 0,025</p>  |
| <p>2-methyl-2H-isothiazol-3-one (MIT)</p> | <p>2682-20-4<br/>220-239-6<br/>01-2120764690-50-XXXX</p> | <p>Acute Tox. 3; H301<br/>Acute Tox. 2; H330<br/>Acute Tox. 3; H311<br/>Skin Corr. 1B; H314<br/>Eye Dam. 1; H318<br/>Skin Sens. 1A; H317<br/>Aquatic Acute 1; H400<br/>Aquatic Chronic 1; H410<br/>EUH071</p> <hr/> <p>M-Factor (Acute aquatic toxicity): 1010<br/>M-Factor (Chronic aquatic toxicity): 11</p> <hr/> <p>specific concentration limit<br/>Skin Sens. 1A; H317<br/>&gt;= 0,0015 %<br/>Skin Sens. 1A; H317<br/>&gt;= 0,0015 %</p> | <p>&gt;= 0,0002 - &lt; 0,0015</p> |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

|   |   |   |                               |
|---|---|---|-------------------------------|
| <p>mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) (C(M)IT/MIT (3:1))</p> | <p>55965-84-9<br/>911-418-6<br/>01-2120764691-48-XXXX</p> | <p>Acute Tox. 3; H301<br/>Acute Tox. 2; H330<br/>Acute Tox. 2; H310<br/>Skin Corr. 1C; H314<br/>Eye Dam. 1; H318<br/>Skin Sens. 1A; H317<br/>Aquatic Acute 1;<br/>H400<br/>Aquatic Chronic 1;<br/>H410<br/>EUH071</p> <hr/> <p>M-Factor (Acute aquatic toxicity):<br/>100100<br/>M-Factor (Chronic aquatic toxicity):<br/>100100</p> <hr/> <p>specific concentration limit<br/>Skin Corr. 1C; H314<br/>≥ 0,6 %<br/>Skin Irrit. 2; H315<br/>0,06 - &lt; 0,6 %<br/>Eye Irrit. 2; H319<br/>0,06 - &lt; 0,6 %<br/>Skin Sens. 1A; H317<br/>≥ 0,0015 %<br/>Eye Dam. 1; H318<br/>≥ 0,6 %<br/>Skin Corr. 1C; H314<br/>≥ 0,6 %<br/>Skin Irrit. 2; H315<br/>0,06 - &lt; 0,6 %<br/>STOT RE 2; H319<br/>0,06 - &lt; 0,6 %<br/>Skin Sens. 1A; H317<br/>≥ 0,0015 %<br/>Eye Dam. 1; H318<br/>≥ 0,6 %</p> | <p>≥ 0,0002 - &lt; 0,0015</p> |
|---|---|---|-------------------------------|

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

|                 |  |   |                      |
|-----------------|--|---|----------------------|
| pyrithione zinc | 13463-41-7<br>236-671-3<br>01-2119511196-46-XXXX | Acute Tox. 3; H301<br>Acute Tox. 2; H330<br>Eye Dam. 1; H318<br>Repr. 1B; H360D<br>STOT RE 1; H372<br>Aquatic Acute 1;<br>H400<br>Aquatic Chronic 1;<br>H410<br><br>M-Factor (Acute aquatic toxicity):<br>1.0001.000<br>M-Factor (Chronic aquatic toxicity):<br>10010<br><br>Acute toxicity estimate<br><br>Acute oral toxicity:<br>221 mg/kg<br>221 mg/kg<br>Acute inhalation toxicity (dust/mist): 0,14 mg/l<br>0,14 mg/l | >= 0,0002 - < 0,0025 |
| terbutryn       | 886-50-0<br>212-950-5                            | Acute Tox. 4; H302<br>Skin Sens. 1; H317<br>Aquatic Acute 1;<br>H400<br>Aquatic Chronic 1;<br>H410<br><br>M-Factor (Acute aquatic toxicity): 100<br>M-Factor (Chronic aquatic toxicity): 100  | >= 0,0002 - < 0,0025 |

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice : Move out of dangerous area.  
Consult a physician.  
Show this safety data sheet to the doctor in attendance.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

- If inhaled : Move to fresh air.  
Consult a physician after significant exposure.
- In case of skin contact : Take off contaminated clothing and shoes immediately.  
Wash off with soap and plenty of water.  
If symptoms persist, call a physician.
- In case of eye contact : Remove contact lenses.  
Keep eye wide open while rinsing.  
If eye irritation persists, consult a specialist.
- If swallowed : Do not induce vomiting without medical advice.  
Rinse mouth with water.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.

### 4.2 Most important symptoms and effects, both acute and delayed

- Symptoms : Allergic reactions  
See Section 11 for more detailed information on health effects and symptoms.
- Risks : sensitising effects  
  
May cause an allergic skin reaction.

### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

- Suitable extinguishing media : In case of fire, use water/water spray/water jet/carbon dioxide/sand/foam/alcohol resistant foam/chemical powder for extinction.

### 5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Do not allow run-off from fire fighting to enter drains or water courses.
- Hazardous combustion products : No hazardous combustion products are known

### 5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

Further information : Collect contaminated fire extinguishing water separately. This must not be discharged into drains.  
Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Deny access to unprotected persons.

#### 6.2 Environmental precautions

Environmental precautions : Do not flush into surface water or sanitary sewer system.  
If the product contaminates rivers and lakes or drains inform respective authorities.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust).  
Keep in suitable, closed containers for disposal.

#### 6.4 Reference to other sections

For personal protection see section 8.

---

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

Advice on safe handling : Avoid exceeding the given occupational exposure limits (see section 8).  
Do not get in eyes, on skin, or on clothing.  
For personal protection see section 8.  
Persons with a history of skin sensitisation problems or asthma, allergies, chronic or recurrent respiratory disease should not be employed in any process in which this mixture is being used.  
Smoking, eating and drinking should be prohibited in the application area.  
Follow standard hygiene measures when handling chemical products

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Hygiene measures : Handle in accordance with good industrial hygiene and safety



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

practice. When using do not eat or drink. When using do not smoke. Wash hands before breaks and at the end of workday.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep container tightly closed in a dry and well-ventilated place. Store in accordance with local regulations.

Further information on storage stability : No decomposition if stored and applied as directed.

### 7.3 Specific end use(s)

Specific use(s) : Consult most current local Product Data Sheet prior to any use.

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

| Components  | CAS-No.    | Value type (Form of exposure) | Control parameters * | Basis * |
|---|------------|-------------------------------|----------------------|---------|
| titanium dioxide; [in powder form containing 1 % or more of particles with aerodynamic diameter $\leq 10 \mu\text{m}$ ] | 13463-67-7 | TWA (inhalable dust)          | 10 mg/m <sup>3</sup> | GB EH40 |
|   |            | TWA (Respirable dust)         | 4 mg/m <sup>3</sup>  | GB EH40 |

\*The above mentioned values are in accordance with the legislation in effect at the date of the release of this safety data sheet.

### 8.2 Exposure controls

#### Engineering measures

Maintain air concentrations below occupational exposure standards.  
Ensure adequate ventilation, especially in confined areas.

#### Personal protective equipment

Eye protection : Safety glasses with side-shields conforming to EN166  
Eye wash bottle with pure water

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard must be worn at all times when handling chemical products. Reference number EN 374. Follow manufacturer specifications.

Suitable for short time use or protection against splashes:  
Butyl rubber/nitrile rubber gloves (> 0,1 mm)  
Contaminated gloves should be removed.  
Suitable for permanent exposure:  
Viton gloves (0.4 mm),  
breakthrough time >30 min.

Skin and body protection : Protective clothing (e.g. Safety shoes acc. to EN ISO 20345,

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

Respiratory protection : long-sleeved working clothing, long trousers). Rubber aprons and protective boots are additionally recommended for mixing and stirring work.  
: In case of inadequate ventilation wear respiratory protection. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.  
organic vapor filter (Type A)  
A1: < 1000 ppm; A2: < 5000 ppm; A3: < 10000 ppm  
Ensure adequate ventilation. This can be achieved by local exhaust extraction or by general ventilation. (EN 689 - Methods for determining inhalation exposure). This applies in particular to the mixing / stirring area. In case this is not sufficient to keep the concentrations under the occupational exposure limits then respiration protection measures must be used.

### Environmental exposure controls

General advice : Do not flush into surface water or sanitary sewer system. If the product contaminates rivers and lakes or drains inform respective authorities.

---

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state : liquid  
Appearance : paste  
  
Boiling point/boiling range : No data available  
  
Flash point : Not applicable  
  
Auto-ignition temperature : No data available  
  
**Viscosity**  
Viscosity, dynamic : 160 - 240 mPa.s  
  
Vapour pressure : 0,01 hPa  
  
Density : 1,75 - 1,95 g/cm<sup>3</sup> (20 °C)

### 9.2 Other information

No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

No dangerous reaction known under conditions of normal use.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

### 10.2 Chemical stability

The product is chemically stable.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : No hazards to be specially mentioned.

### 10.4 Conditions to avoid

Conditions to avoid : No data available

### 10.5 Incompatible materials

Materials to avoid : No data available

### 10.6 Hazardous decomposition products

No decomposition if stored and applied as directed.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

#### Acute toxicity

Not classified based on available information.

#### Components:

##### **2-octyl-2H-isothiazole-3-one (OIT):**

Acute oral toxicity : Acute toxicity estimate: 125 mg/kg  
Method: Acute toxicity estimate according to Regulation (EC) No. 1272/2008

Acute toxicity estimate: 125 mg/kg  
Method: Acute toxicity estimate according to Regulation (EC) No. 1272/2008

Acute inhalation toxicity : Acute toxicity estimate: 0,27 mg/l  
Test atmosphere: dust/mist  
Method: Acute toxicity estimate according to Regulation (EC) No. 1272/2008

Acute toxicity estimate: 0,27 mg/l  
Test atmosphere: dust/mist  
Method: Acute toxicity estimate according to Regulation (EC) No. 1272/2008

Acute dermal toxicity : Acute toxicity estimate: 311 mg/kg  
Method: Acute toxicity estimate according to Regulation (EC) No. 1272/2008

Acute toxicity estimate: 311 mg/kg

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

Method: Acute toxicity estimate according to Regulation (EC)  
No. 1272/2008

### **1,2-benzisothiazol-3(2H)-one (BIT):**

- Acute oral toxicity : LD50 Oral (Rat): 597 mg/kg
- Acute inhalation toxicity : LC50: 0,4 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403
- Acute dermal toxicity : LD50 Dermal (Rabbit): > 2.000 mg/kg

### **2-methyl-2H-isothiazol-3-one (MIT):**

- Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) (C(M)IT/MIT (3:1)):

- Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

### **pyrithione zinc:**

- Acute oral toxicity : Acute toxicity estimate: 221 mg/kg  
Method: Acute toxicity estimate according to Regulation (EC)  
No. 1272/2008
- Acute toxicity estimate: 221 mg/kg  
Method: Acute toxicity estimate according to Regulation (EC)  
No. 1272/2008
- Acute inhalation toxicity : Acute toxicity estimate: 0,14 mg/l  
Test atmosphere: dust/mist  
Method: Acute toxicity estimate according to Regulation (EC)  
No. 1272/2008
- Acute toxicity estimate: 0,14 mg/l  
Test atmosphere: dust/mist  
Method: Acute toxicity estimate according to Regulation (EC)  
No. 1272/2008

### **Skin corrosion/irritation**

Not classified based on available information.

### **Serious eye damage/eye irritation**

Not classified based on available information.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

### Respiratory or skin sensitisation

#### Skin sensitisation

May cause an allergic skin reaction.

#### Respiratory sensitisation

Not classified based on available information.

#### Germ cell mutagenicity

Not classified based on available information.

#### Carcinogenicity

Not classified based on available information.

#### Reproductive toxicity

Not classified based on available information.

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

#### Aspiration toxicity

Not classified based on available information.

### 11.2 Information on other hazards

#### Endocrine disrupting properties

##### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **2-octyl-2H-isothiazole-3-one (OIT):**

M-Factor (Acute aquatic toxicity) : 100

100

M-Factor (Chronic aquatic toxicity) : 100

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

100

### 1,2-benzisothiazol-3(2H)-one (BIT):

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia (water flea)): 3 mg/l  
Exposure time: 48 h

### 2-methyl-2H-isothiazol-3-one (MIT):

M-Factor (Acute aquatic toxicity) : 10

10

M-Factor (Chronic aquatic toxicity) : 1

1

mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) (C(M)IT/MIT (3:1)):

M-Factor (Acute aquatic toxicity) : 100

100

M-Factor (Chronic aquatic toxicity) : 100

100

### pyrithione zinc:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 0,0026 mg/l  
Exposure time: 96 h

M-Factor (Acute aquatic toxicity) : 1.000

1.000

M-Factor (Chronic aquatic toxicity) : 100

10

### terbutryn:

M-Factor (Acute aquatic toxicity) : 100

M-Factor (Chronic aquatic toxicity) : 100

## 12.2 Persistence and degradability

No data available

## 12.3 Bioaccumulative potential

No data available

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher..

### 12.6 Endocrine disrupting properties

**Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

**Product:**

Additional ecological information : An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.  
Toxic to aquatic life with long lasting effects.

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : The generation of waste should be avoided or minimized wherever possible.  
Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe way.  
Dispose of surplus and non-recyclable products via a licensed waste disposal contractor.  
Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements.  
Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Contaminated packaging : 15 01 10\* packaging containing residues of or contaminated by dangerous substances

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

---

### SECTION 14: Transport information

#### 14.1 UN number

**ADR** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

#### 14.2 UN proper shipping name

**ADR** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

**ADR** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

#### 14.4 Packing group

**ADR** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA (Cargo)** : Not regulated as a dangerous good  
**IATA (Passenger)** : Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

#### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Not applicable for product as supplied.

---

### SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3

International Chemical Weapons Convention (CWC) Schedules of Toxic Chemicals and Precursors : Not applicable



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

|  |   |   |
|--|---|---|
| REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).                                      | : | None of the components are listed (= > 0.1 %).  |
| REACH - List of substances subject to authorisation (Annex XIV)  | : | Not applicable  |
| Regulation (EC) No 1005/2009 on substances that deplete the ozone layer  | : | Not applicable  |
| Regulation (EU) 2019/1021 on persistent organic pollutants (recast)  | : | Not applicable  |
| Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals | : | Not applicable  |
| REACH Information:   |   | All substances contained in our Products are<br>- registered by our upstream suppliers, and/or<br>- registered by us, and/or<br>- excluded from the regulation, and/or<br>- exempted from the registration. |

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

E2 ENVIRONMENTAL HAZARDS

Volatile organic compounds : Law on the incentive tax for volatile organic compounds (VOCV)  
no VOC duties

Directive 2010/75/EU of 24 November 2010 on industrial emissions (integrated pollution prevention and control)  
Not applicable

If other regulatory information applies that is not already provided elsewhere in the Safety Data Sheet, then it is described in this subsection.

Health, safety and environmental regulation/legislation specific for the substance or mixture: : Environmental Protection Act 1990 & Subsidiary Regulations  
Health and Safety at Work Act 1974 & Subsidiary Regulations  
Control of Substances Hazardous to Health Regulations (COSHH)  
May be subject to the Control of Major Accident Hazards Regulations (COMAH), and amendments.

### 15.2 Chemical safety assessment

No Chemical Safety Assessment has been carried out for this mixture by the supplier.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021  
Revision Date: 31.08.2021

Version 1.1

Print Date 31.08.2021

### SECTION 16: Other information

#### Full text of H-Statements

|       |   |
|-------|---|
| H301  | : Toxic if swallowed.   |
| H302  | : Harmful if swallowed.   |
| H310  | : Fatal in contact with skin.                                     |
| H311  | : Toxic in contact with skin.                                     |
| H314  | : Causes severe skin burns and eye damage.                        |
| H315  | : Causes skin irritation.   |
| H317  | : May cause an allergic skin reaction.                            |
| H318  | : Causes serious eye damage.                                      |
| H330  | : Fatal if inhaled.   |
| H351  | : Suspected of causing cancer if inhaled.                         |
| H360D | : May damage the unborn child.                                    |
| H372  | : Causes damage to organs through prolonged or repeated exposure. |
| H400  | : Very toxic to aquatic life.                                     |
| H410  | : Very toxic to aquatic life with long lasting effects.           |
| H411  | : Toxic to aquatic life with long lasting effects.                |

#### Full text of other abbreviations

|                 |   |
|-----------------|---|
| Acute Tox.      | : Acute toxicity  |
| Aquatic Acute   | : Short-term (acute) aquatic hazard   |
| Aquatic Chronic | : Long-term (chronic) aquatic hazard  |
| Carc.           | : Carcinogenicity   |
| Eye Dam.        | : Serious eye damage  |
| Repr.           | : Reproductive toxicity   |
| Skin Corr.      | : Skin corrosion  |
| Skin Irrit.     | : Skin irritation   |
| Skin Sens.      | : Skin sensitisation  |
| STOT RE         | : Specific target organ toxicity - repeated exposure  |
| GB EH40         | : UK. EH40 WEL - Workplace Exposure Limits  |
| GB EH40 / TWA   | : Long-term exposure limit (8-hour TWA reference period)  |
| ADR             | : European Agreement concerning the International Carriage of Dangerous Goods by Road   |
| CAS             | : Chemical Abstracts Service  |
| DNEL            | : Derived no-effect level   |
| EC50            | : Half maximal effective concentration  |
| GHS             | : Globally Harmonized System  |
| IATA            | : International Air Transport Association   |
| IMDG            | : International Maritime Code for Dangerous Goods   |
| LD50            | : Median lethal dose (the amount of a material, given all at once, which causes the death of 50% (one half) of a group of test animals) |
| LC50            | : Median lethal concentration (concentrations of the chemical in air that kills 50% of the test animals during the observation period)  |
| MARPOL          | : International Convention for the Prevention of Pollution from Ships, 1973 as modified by the Protocol of 1978                         |
| OEL             | : Occupational Exposure Limit   |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Parex® REVLANE+ IGNIFUGE TALOCHE FIN

Date of last issue: 22.06.2021

Version 1.1

Print Date 31.08.2021

Revision Date: 31.08.2021

|       |   |  |
|-------|---|--|
| PBT   | : | Persistent, bioaccumulative and toxic  |
| PNEC  | : | Predicted no effect concentration  |
| REACH | : | Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency |
| SVHC  | : | Substances of Very High Concern  |
| vPvB  | : | Very persistent and very bioaccumulative   |

### Further information

#### Classification of the mixture:

|                   |      |
|-------------------|------|
| Skin Sens. 1      | H317 |
| Aquatic Chronic 2 | H411 |

#### Classification procedure:

|                    |
|--------------------|
| Calculation method |
| Calculation method |

The information contained in this Safety Data Sheet corresponds to our level of knowledge at the time of publication. All warranties are excluded. Our most current General Sales Conditions shall apply. Please consult the product data sheet prior to any use and processing.



Changes as compared to previous version !

GB / EN